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Background: Pregnancy induces adaptations in maternal metabolism to meet the increased need for nutrients by
the placenta and fetus. Creatine is an important intracellular metabolite obtained from the diet and also synthesised
endogenously. Experimental evidence suggests that the fetus relies on a maternal supply of creatine for much of
gestation. However, the impact of pregnancy on maternal creatine homeostasis is unclear. We hypothesise that
alteration of maternal creatine homeostasis occurs during pregnancy to ensure adequate levels of this essential
substrate are available for maternal tissues, the placenta and fetus. This study aimed to describe maternal creatine
homeostasis from mid to late gestation in the precocial spiny mouse.
Methods: Plasma creatine concentration and urinary excretion were measured from mid to late gestation in
pregnant (n = 8) and age-matched virgin female spiny mice (n = 6). At term, body composition and organ
weights were assessed and tissue total creatine content determined. mRNA expression of the creatine synthesising
enzymes arginine:glycine amidinotransferase (AGAT) and guanidinoacetate methyltransferase (GAMT), and the creatine
transporter (CrT1) were assessed by RT-qPCR. Protein expression of AGAT and GAMT was also assessed by western blot
analysis.
Results: Plasma creatine and renal creatine excretion decreased significantly from mid to late gestation (P < 0.001,
P < 0.05, respectively). Pregnancy resulted in increased lean tissue (P < 0.01), kidney (P < 0.01), liver (P < 0.01) and heart
(P < 0.05) mass at term. CrT1 expression was increased in the heart (P < 0.05) and skeletal muscle (P < 0.05) at term
compared to non-pregnant tissues, and creatine content of the heart (P < 0.05) and kidney (P < 0.001) were also
increased at this time. CrT1 mRNA expression was down-regulated in the liver (<0.01) and brain (<0.01) of pregnant
spiny mice at term. Renal AGAT mRNA (P < 0.01) and protein (P < 0.05) expression were both significantly up-regulated
at term, with decreased expression of AGAT mRNA (<0.01) and GAMT protein (<0.05) observed in the term pregnant
heart. Brain AGAT (<0.01) and GAMT (<0.001) mRNA expression were also decreased at term.
Conclusion: Change of maternal creatine status (increased creatine synthesis and reduced creatine excretion) may be a
necessary adjustment of maternal physiology to pregnancy to meet the metabolic demands of maternal tissues, the
placenta and developing fetus.
Keywords: Nutrition, Cellular energy, Metabolism, Pregnancy, Fetal development, Spiny mouse* Correspondence: stacey.ellery@monash.edu
1The Ritchie Centre, MIMR-PHI Institute of Medical Research, 27-31 Wright St,
Clayton, Melbourne 3168, Australia
2Department of Obstetrics & Gynaecology, Monash University, Monash
Medical Centre, Clayton, Melbourne, Australia
Full list of author information is available at the end of the article
© 2015 Ellery et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Ellery et al. BMC Pregnancy and Childbirth  (2015) 15:92 Page 2 of 9Background
Maternal metabolic adaptations are required during preg-
nancy to meet the nutrient demands of the growing pla-
centa and fetus [1]. These changes include shifts into
anabolic metabolism during the first and second trimes-
ters [2]. This allows for fat accumulation in the mother, to
be used as an energy source for maternal tissues during
the third trimester, when a switch to catabolic metabolism
takes place to ensure an enhanced nutrient supply to the
growing fetus [2-6]. These adaptations to meet fetal re-
quirements for growth encompass large changes in mater-
nal glucose, carbohydrate, amino acid, lipid and fatty acid
metabolism [2,7]. An inability of the maternal system to
make these adjustments and ensure appropriate nutrient
supply for both maternal and fetal tissues may underpin
some of the obstetric complications associated with poor
fetal growth and placental insufficiency [8].
While creatine is thought to be an essential metabolite
for the growing fetus [9,10], whether maternal creatine
metabolism is altered in pregnancy has received little
attention. Creatine and its intracellular phosphorylated de-
rivative, phosphocreatine, have an important role in cellu-
lar ATP turnover [11]. Creatine is readily obtained from a
diet of animal products and is also synthesised by the body
through the production of guanidinoacetate (GAA), cata-
lysed by the enzyme arginine:glycine aminotransferase
(AGAT) predominately in the kidney, followed by the
methylation of GAA, mainly in the liver, to produce creat-
ine [12]. Once synthesised or absorbed creatine is moved
into tissues by the creatine transporter-1 protein (CrT1)
[13] where ~75% is phosphorylated and used as a source
of phosphate for the regeneration of ATP [14].
Creatine has been shown to cross the human placenta
[10]. However the source of this creatine is not known. In
rats, AGAT, GAMT, and CrT1 are expressed in most tis-
sues of the embryo from early in gestation [15]. Yet studies
in the spiny mouse, a precocial species that has a number
of reproductive similarities to human pregnancy in terms
of in utero organ development [16-18] and endocrine func-
tion [19], identified that creatine was accrued during gesta-
tion by the placenta and fetal tissues, but that the fetus had
limited capacity for creatine synthesis until 0.9 of gestation
[20]. This suggests that creatine supply to the placenta and
fetus in mammals that give birth to well-developed young
is maternal in origin for much of gestation. This raises
questions about how the maternal system provides for the
proposed increase in need for creatine during pregnancy.
Thus, the objective of this study was to describe maternal
creatine homeostasis during gestation in the spiny mouse.
Methods
Spiny mice
All experiments were approved in advance by Monash
University Animal Ethics Committee and conducted inaccordance with the Australian Code of Practice for the
Care and Use of Animals for Scientific Purposes. Spiny
mice (Acomys cahirinus) were bred and housed as previ-
ously described [21]. Pregnant and virgin female spiny
mice were used to conduct this study. Control females
and near-term pregnant dams (37 days gestation [dGA];
term is 39 days) were killed by cervical dislocation and
the brain, liver, kidney, heart and gastrocnemius muscle
were excised, weighed, snap frozen and stored at −80°C.
Body composition
After post mortem whole frozen bodies (non-pregnant
n = 6; pregnant n = 6 (excluding the uterus and fetal tis-
sues for the pregnant cohort)) were subjected to Dual-
energy X-ray absorptiometry (DEXA; Lunar PIXImus,
GE Medical Systems, Wisconsin), for assessment of lean
tissue mass, bone mineral density (BMD) and tissue fat
mass [22].
Urine collection
Non-pregnant females (n = 6), and pregnant dams (n = 6)
at 23dGA and 35dGA were placed in a metabolic cage
apparatus (Monash Scientific Glass, Dandenong, Victoria)
for 12 hours (h) during the dark cycle (19:00–07:00) to
facilitate the collection of urine for measurement of
creatine. Food and water intake were also measured
during this time.
Plasma collection
Non-pregnant female spiny mice (n = 6) and pregnant
dams (23dGA, 35dGA and term) (n = 6-9/time-point)
were anesthetised and whole blood was collected by cardiac
puncture, before the spiny mice were killed by cervical dis-
location. Whole blood was centrifuged at 4°C and 3000 g
for 10 mins. Plasma was then frozen and stored at −20°C.
Measuring creatine
Tissues (brain, liver, kidney, heart, gastrocnemius muscle;
3–4 mg) were freeze-dried, powdered and extracted with
0.5 mol/L perchloric acid and 1 mmol/L ethylenediamine-
tetraacetic acid (EDTA) before being neutralized with
2.1 mol/L potassium hydrogen carbonate. Plasma and urine
were extracted with 1.5 M perchloric acid (50 μl acid/
100 μl sample) before being neutralized with 2.1 mol/L
potassium hydrogen carbonate. Extracted samples were
used to determine total creatine content by enzymatic
analysis of creatine and phosphocreatine with fluorometric
detection as previously described [9,23,24]. Wet:dry tissue
weight ratios were used to calculate estimated total creat-
ine content per organ for kidney, liver, brain and heart
samples. The calculated urinary excretion rate of creatine
was based on the volume of urine collected over the 12 h
period.
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Real-time quantitative polymerase chain reaction (RT-
qPCR) was used to determine the mRNA expression of
the creatine transporter-1 (CrT1) (SLC6A8) [GenBank:
NM_ 133987.2] and creatine synthesising enzymes
AGAT (GATM) [GenBank: NM_025961] and GAMT
[GenBank: NM_010255.3] in the brain, liver, kidney,
heart and gastrocnemius muscle as described previously
[20]. Cyclophilin A (peptidylprolyl isomeraseA; PPIA)
[GenBank: NM_017101.1] was used as the housekeeping
gene. Primer sequences are shown in Table 1. Total RNA
was extracted using RNeasy Kits (Qiagen, Glen Forrest,
Australia) and reverse transcribed, according to manufac-
turer’s instructions (Promega, Madison, Wisconsin). RT-
qPCR was completed using a Stratagene MX3000p thermal
cycler system with SYBR green PCR Mastermix (Applied
Biosystems, Carlsband, California). Cycling conditions
were: 95°C 10mins; 95°C 15secs, 60°C 1 min ×40 cycles;
95°C 5secs, 60°C 15secs, 95°C 15secs ×40 cycles. Data ob-
tained from qPCR were analysed using the ΔΔCT method
[20,25], with results expressed relative to non-pregnant
controls.
Protein expression
Frozen tissues (~10 mg) were solubilised in 12.5% Tris–
HCl (pH 6.8), 10% Glycerol, 20% of 0.1 SDS/ dH2O and
10% protease inhibitor in dH2O overnight. Samples were
centrifuged and protein concentration of supernatants
determined by the bicinchoninic acid assay, following
manufacturers instructions (BCA Protein Assay Kit#23225,
Thermo Scientific, Scoresby, Australia). Aliquots of samples
at a final protein concentration of 40 μg were separated by
SDS-PAGE using Novex NuPAGE precast Tris-base 4-12%
gels according to manufacturer’s instructions (Life Tech-
nologies, Mulgrave, Victoria). To account for inter-gel vari-
ability, samples from all groups were included on each gel
and protein samples extracted from an adult spiny mouse
kidney (AGAT) and liver (GAMT) used as an internal con-
trol across all gels. Protein was transferred to PVDF mem-
branes, blocked for 1-h in 5% skim milk buffer (SMB) and
incubated overnight in 1:70 anti-AGAT (Biorbyt, GATM
antibody, orb28345, Cambridgeshire, United Kingdom,
band size 47 kDa) or 1:250 anti-GAMT in 2.5% SMB (an
affinity purified mouse monoclonal antibody, made through
injection of the antigenic peptide N-terminal aa 125–145,Table 1 Primer Sequences
Gene Accession number (GenBank) Forward pri
CrT1 (SLC6A8) NM_133987.2 TCCTGGCAC
AGAT (GATM) NM_025961 TCACGCTTCT
GAMT NM_010255.3 TGGCACACT
Cyclophilin A (PPIA) NM_017101.1 CTGATGGCG
Oligonucleotide primer sequences used for the amplification and RT-qPCR analysisband size 26 kDa; Monash Antibody Technologies Facility,
Melbourne, Australia). Membranes were then incu-
bated for 1-h with fluorescent secondary antibodies
(Anti-Mouse IgG(H+ L) Daylight™ 680 Conjugate or Anti-
Rabbit IgG(H+ L) Daylight™ 800 Conjugate; Cell Signalling
Technologies®, Danvers, USA), before being scanned using
the LiCOR® OdysseyCLx® Imaging System (Millennium
Science, Mulgrave, Victoria). Membranes were then re-
probed as above for GAPDH (G8795, Sigma-Aldrich,
Castle Hill, NSW, band size 37 kDa), which was used
as the loading control. Protein expression was determined
by densitometry using Image Studio Lite™ software. Re-
sults are presented relative to non-pregnant controls.
Note: due to the lack of a specific CrT1 antibody we were
unable to perform western blots for this protein [26,27].Data analysis and statistics
Data are presented as means ± SEM. A Students t-Test
for two independent samples was used to compare body
composition, organ weights, tissue creatine content, and
expression of creatine synthesising enzymes between
pregnant and non-pregnant animals. A One-Way
ANOVA with Bonferroni’s correction for multiple com-
parisons was used to assess plasma creatine concentra-
tion and urinary creatine excretion, by comparing the
difference at two time-points during pregnancy to the
non-pregnant controls. Prism 6 Graphpad software™ was
used to perform statistical comparisons.Results
Body composition and organ weights
At term the bone mineral density of pregnant spiny mice
was significantly lower (14%) compared to non-pregnant
females (Table 2; P < 0.05). Maternal lean tissue mass
was increased with pregnancy by 16% (Table 2; P < 0.01),
with no evident change in tissue fat mass (Table 2). Kid-
ney mass was 26% greater at term in the pregnant spiny
mouse compared to non-pregnant controls (Table 3; P <
0.01). Liver mass of pregnant spiny mice was also greater
than controls by 29% (Table 3; P < 0.01) and hypertrophy
of the heart in pregnant spiny mice was evident with a
12% increase in mass (Table 3; P < 0.05). No change in
brain weight was observed between non-pregnant and





of creatine synthesizing enzymes and the creatine transporter.
Table 2 Whole Body Dual X-ray Absorptiometry
Dual X-ray Absorptiometry Non-pregnant Pregnant Statistics
BMD (g/cm2) 0.066 ± 0.001 0.057 ± 0.001 <0.05
Tissue- Lean Mass (g) 24.9 ± 0.6 29.6 ± 1.3 <0.01
Tissue- Fat Mass (g) 8.7 ± 0.6 9.0 ± 0.6 NS
The effect of pregnancy on bone mineral denisty (BMD; g/cm2), tissue lean
mass (g) and tissue fat mass (g). Values are means ± SEM; n = 6-8/group.
Statistical analysis Students t-Test. Significance P ≤ 0.05.
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Plasma creatine levels were significantly lower in preg-
nant compared to non-pregnant spiny mice (Figure 1A;
P < 0.001) with the greater part of this decrease having
occurred by 23dGA (0.58 gestation). Urinary creatine ex-
cretion was significantly lower in pregnant spiny mice
than non-pregnant controls (Figure 1B; P < 0.05), with cre-
atine excretion decreasing significantly between 23dGA
and 35dGA (P < 0.01). No difference in food intake, from
which dietary creatine consumption was calculated, was
noted between non-pregnant and pregnant spiny mice at
23dGA or 35dGA (data not shown).
AGAT and GAMT expression
Renal expression of AGAT, measured as mRNA and pro-
tein, were both significantly increased during pregnancy
(Figure 2A & B; P < 0.01, P < 0.05, respectively). In contrast
to the kidney, AGAT mRNA expression in the heart was
lower in pregnant dams compared to non-pregnant con-
trols (Table 4; P < 0.01), and there was a strong trend for
heart AGAT protein expression to be lower with preg-
nancy (P = 0.054). AGAT mRNA expression was also sig-
nificantly lower in the brain (P < 0.01) and gastrocnemius
muscle (P < 0.01) of term pregnant dams compared to
their non-pregnant counterparts, but with no significant
change in the amount of AGAT protein present in these
tissues (Table 4).
Analysis of hepatic GAMT identified no difference in
mRNA expression between the pregnant and non-
pregnant groups (Figure 2C), however GAMT protein ex-
pression was significantly decreased in the liver of term
pregnant spiny mice compared to non-pregnant controls
(Figure 2D; P < 0.01). GAMT mRNA (P < 0.001) and pro-
tein (P < 0.05) were both lower in the maternal brain at
term compared to the brain in non-pregnant spiny miceTable 3 Organ Weights
Organs Non-pregnant Pregnant Statistics
Kidney (mg) 225.5 ± 11.0 305.1 ± 8.7 <0.01
Liver (g) 0.899 ± 0.001 1.26 ± 0.05 <0.01
Heart (mg) 119.5 ± 9.1 134.7 ± 4.1 <0.05
Brain (mg) 823.8 ± 12.9 864.6 ± 10.7 NS
The weight (mg or g) of non-pregnant and term pregnant spiny mouse kidney,
liver, heart and brain. Values are means ± SEM; n = 6-8/group for organ
weights. Statistical analysis Students t-Test. Significance P ≤ 0.05.(Table 4). Pregnancy was also associated with an increase
in GAMT protein expression in maternal cardiac homoge-
nates at term (Table 4; P < 0.01).
Expression of CrT1 and tissue creatine content
Cardiac CrT1 mRNA expression was significantly higher
in pregnant dams compared to non-pregnant controls
(Figure 3C; P < 0.05), as was the creatine content of the
heart (Table 5; P < 0.05). While pregnancy had no effect
on creatine content in the liver (Table 5), hepatic CrT1
mRNA was significantly lower in pregnant dams com-
pared to non-pregnant controls (Figure 3A; P < 0.001).
The creatine content in the brain was also not different
between pregnant and non-pregnant females (Table 5),
although brain CrT1 mRNA expression was significantly
decreased in pregnant dams (Figure 3B; P < 0.01). Up-
regulation of CrT1 mRNA in the gastrocnemius muscle
was also observed with pregnancy (Figure 3D; P < 0.05),
but creatine content in the gastrocnemius muscle was
not different between pregnant and non-pregnant spiny
mice (Table 5). The renal expression of CrT1 mRNA
was not different between pregnant and non-pregnant
spiny mice, however a significant increase in kidney
creatine content was detected with pregnancy (Table 5;
P < 0.001).
Discussion
To our knowledge this is the first study to document
changes in maternal creatine metabolism during preg-
nancy. As creatine delivery to the placenta and fetus ap-
pears to be of maternal origin in precocial species,
changes to maternal creatine homeostasis maybe a ne-
cessary adjustment of maternal metabolism to pregnancy
in much the same way that alterations to glucose, amino
acid, carbohydrate, lipid and fatty acid metabolism are
required to support growing maternal tissues, the pla-
centa and fetus [2].
Changes to creatine demand during pregnancy
development
Maternal plasma creatine concentrations and urinary
creatine excretion were both significantly decreased in
pregnancy. The rate of entry and removal of creatine
into the plasma should be considered when interpret-
ing these findings. Typically, entry of creatine into the
maternal plasma would involve its absorption across
the gut following ingestion of dietary creatine, and/or
the release of creatine into the circulation from organs
involved in de novo synthesis, mainly the liver [11]. Re-
moval of circulating creatine may occur during pregnancy
by the active transport of creatine into maternal tissues,
the spontaneous (non-enzymatic) conversion of creatine
to creatinine, excretion of creatine in the urine, or the
transfer of creatine across the placenta [9,10,28,29].
Figure 1 Maternal Plasma Creatine Concentration and Urinary Creatine Concentration from Mid to Late Gestation. (A) Plasma creatine concentration
(μmol/L) of non-pregnant controls and pregnant spiny mice at 23d GA, 35d GA and term. (B) Urinary creatine excretion (mgCr/12 h) in non-pregnant
and pregnant spiny mice at 23d GA and 35d GA. Values are means ± SEM; n = 6-8/group. Statistical analysis One-Way ANOVA with Bonferroni Multiple
Comparisons. Significance P≤ 0.05; *P <0.05, **P < 0.01, ***P < 0.001.
Figure 2 Maternal AGAT and GAMT Expression in the Kidney and Liver. Maternal kidney AGAT mRNA (A) and protein (B) expression significantly
increased at term, compared to non-pregnant controls. No change in liver GAMT mRNA (C) was observed, however GAMT protein was decreased
at term (D). Data are expressed relative to the house keeping gene/protein. Values are means ± SEM; n = 6-8/group. Statistical analysis Students
t-Test. Significance P < 0.05; *P <0.05.
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Table 4 Tissue AGAT and GAMT Expression
Brain Heart Gastrocnemius muscle
Non-pregnant Pregnant Stats Non-pregnant Pregnant Stats Non-pregnant Pregnant Stats
AGAT mRNA 1.00 ± 0.06 0.48 ± 0.10 <0.01 1.00 ± 0.25 0.20 ± 0.02 <0.01 1.00 ± 0.11 0.40 ± 0.03 <0.01
AGAT Protein 1.00 ± 0.12 0.73 ± 0.18 NS 1.00 ± 0.26 0.46 ± 0.07 0.054 1.00 ± 0.45 1.23 ± 0.65 NS
GAMT mRNA 1.00 ± 0.15 0.23 ± 0.05 <0.001 1.00 ± 0.29 0.68 ± 0.05 NS 1.00 ± 0.13 0.78 ± 0.10 NS
GAMT Protein 1.00 ± 0.46 0.20 ± 0.07 0.05 1.00 ± 0.37 2.27 ± 0.35 <0.05 1.00 ± 0.42 0.77 ± 0.28 NS
mRNA and protein expression of AGAT and GAMT in the brain, heart and skeletal muscle of non-pregnant and pregnant spiny mice at term. Data are expressed
relative to the house keeping gene/protein. Values are means ± SEM; n = 6/group. Statistical analysis Students t-Test. Significance P ≤ 0.05.
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mid to late gestation reported in the spiny mouse limits
the probability that the decline in plasma creatine con-
centration observed in this study is the consequence of
increased creatine loss through the kidney. However, the
decreased renal excretion of creatine may be directly re-
lated to the observed fall in plasma (and hence, filtered)
creatine. Whilst this study did not measure the activity
of the creatine transporter in the kidney, no change in
renal CrT1 gene expression was observed and therefore
creatine uptake from glomerular filtrate may not be dif-
ferent between pregnant and non-pregnant spiny mice.
Expression of monocarboxylate 12 (MCT12), a transport
protein recently identified in kidney tubules and shownFigure 3 Maternal Creatine Transporter Expression. Creatine transporter 1 (
pregnant spiny mice at term. An increase in CrT1 mRNA expression, relative to
muscle (D) of term pregnant spiny mice. Data are expressed relative to the ho
Statistical analysis Students t-Test. Significance P ≤ 0.05; *P <0.01.to perform facilitated diffusion of creatine was also not
assessed in this study, but may play a role in the urinary
creatine recovery observed with pregnancy in the spiny
mouse [30].
The increased CrT1 gene expression identified in the
heart and gastrocnemius muscle of the pregnant spiny
mouse suggests these tissues have an increased capacity
for creatine uptake from the circulation during pregnancy.
Indeed, the pregnant heart had a significantly higher creat-
ine content at term. These increases may reflect the need
for increased phosphate buffering and preservation of
ATP associated with the increased cardiac output of 40-
50% during pregnancy [31,32]. The DEXA results indicate
there was an increase in lean tissue mass of the pregnantCrT1) mRNA expression was reduced in the liver (A) and brain (B) of
non-pregnant controls, was observed in the heart (C) and gastrocnemius
use keeping gene/protein. Values are means ± SEM; n = 6-8/group.
Table 5 Tissue Creatine Content
Tissue creatine content Non-pregnant Pregnant Statistics
Estimated Total Creatine per Organ (nmol)
Kidney 520.9 ± 48.36 912.61 ± 48.36 <0.001
Liver 2432.4 ± 548.3 2554.1 ± 557.8 NS
Brain 14443.0 ± 399.9 12933.7 ± 1109.5 NS
Heart 1540.4 ± 107.7 1899.9 ± 72.36 <0.05
Total Creatine (mmol/kg Dry Weight)
Gastrocnemius Muscle 136.1 ± 9.4 124.1 ± 3.0 NS
Estimated total creatine content per organ (nmol). Data calculated from total
creatine content, wet/dry weight ratio and wet mass per organ, except for the
gastrocnemius muscle (mmol/kg dry mass). Values are means ± SEM; n = 6/group.
Statistical analysis Students t-Test. Significance P ≤ 0.05.
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that skeletal muscle contributes to 38-42% of lean tissue
mass [33,34], and as skeletal muscle is the largest store of
creatine in the body, this increased total mass together
with the increase of CrT1 mRNA in pregnancy would be
expected to result in increased creatine uptake from the
maternal plasma into muscle beds. The adaptive value of
the increased CrT1 expression may be to ensure that
intracellular creatine levels remain at the levels required
for normal muscle function. Mediators of increased CrT1
expression may be IGF-1 and triiodothyronine, both of
which are up-regulated during pregnancy [35,36], and
both of which have been shown to increase CrT1 expres-
sion and creatine uptake in skeletal myoblast cells by virtue
of their effects on the Na+ transmembrane potential [37].
It is also likely that the placenta is an additional ‘sink’
for maternal plasma creatine, given that the creatine
content of placental and fetal tissues increase across ges-
tation [10,20]. What initiates changes in placenta CrT1
expression and creatine transfer during human preg-
nancy remains undetermined. The estrogen-related re-
ceptors (ERRα, β and γ) are highly expressed in the
human placenta from the 2nd trimester and have been
linked with energy metabolism within placental cells
[38,39]. Recently, studies have described the role of
ERRα in the up-regulation of CrT1 mRNA and creatine
uptake in a L6 myotubule cell line [40]. Estrogen-related
receptors may therefore be a prime candidate for facili-
tating creatine uptake into the placenta and maternal
tissues during pregnancy. Interestingly, the spiny mouse
dietary intake of creatine during pregnancy did not appear
to change, suggesting that pregnancy may induce an in-
crease in maternal endogenous creatine synthesis to meet
the demand.
Maternal blood volume was not measured in this study,
but would be expected to increase, as this is a fundamen-
tal, well-characterised adaptation that occurs in both ro-
dent and human pregnancy [41,42]. Plasma expansion
during pregnancy should thus be determined in the spiny
mouse, to elucidate whether increased plasma volumemight partially contribute to the decreased plasma creat-
ine levels observed during pregnancy in this study. It is
also unknown if creatine absorption across the gut is
modified by pregnancy in the spiny mouse or the human.
Changes to the gastrointestinal tract have been well char-
acterised in rodent and human pregnancies, including the
progesterone-induced decrease in gastrointestinal tract
motility [43,44]. These adaptations facilitate increased nu-
trient absorption without an increase in dietary consump-
tion [45]. As creatine absorption is limited to certain
regions of the gut, intestinal transit time is thought to be a
factor in creatine uptake under normal physiological con-
ditions [46,47]. The slowed movement of substances
through the intestine with pregnancy may therefore in-
crease the contact time of creatine with CrT1 sites in the
gut and increase intestinal absorption [48]. The uptake of
creatine through the gut during pregnancy should thus be
considered in future investigations of maternal creatine
homeostasis.
Adaptations to maternal creatine synthesis at term
Pregnancy in the spiny mouse was associated with a
marked increase in maternal kidney AGAT mRNA and
protein expression. As the rate limiting step of creatine
synthesis, an increase in renal AGAT expression is con-
sidered a key indicator of increased endogenous capacity
to synthesise creatine [28]. Whereas renal AGAT protein
expression was greater in the kidney, hepatic GAMT
protein expression (per μg of tissue protein) was de-
creased in pregnant spiny mice. This result suggests that
the maximal rate of GAA methylation and thus creatine
production in the liver may decrease with pregnancy, al-
though this may be offset by the relatively large (29%)
increase in liver size in the pregnant spiny mouse. Fur-
ther work to establish maternal plasma levels of GAA
during pregnancy, and of AGAT and GAMT enzyme ac-
tivities in vivo of the maternal kidney and liver are
needed to address these findings. Consideration of sub-
sidiary sites of creatine synthesis such as the pancreas
[49], and the changes to AGAT and GAMT expression
observed in the brain, heart and gastrocnemius muscle
identified in this study should also be considered when
evaluating global maternal creatine production during
pregnancy.
Clinical translation
Establishing normative values (mean, range) for maternal
plasma creatine and creatine urinary excretion during
human pregnancy would be an important extension of
these findings in the spiny mouse. Particular consideration
should be given to the vegetarian population who obtain
little creatine from their diet, and therefore require
highly competent function of their renal-hepatic axis to
synthesize endogenous creatine. Whether alterations to
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complications such as poor fetal growth and placental
insufficiency should also be considered in human-based
studies. Recent literature suggests targeted dietary sup-
plementation can play an essential role in reducing ob-
stetric complications and neonatal mortality [50,51]. As
a simple dietary intervention, creatine may have the
ability to increase the cellular energy reserves of the
mother, placenta and fetal organs, and may better out-
comes following obstetric complications that lead to
cellular energy failure and/or oxidative stress [52]. In-
deed, previous studies conducted in the spiny mouse
indicate increasing maternal dietary creatine improves
neonatal outcomes following birth asphyxia [53-55].
Conclusions
Pregnancy in the spiny mouse is associated with increased
creatine content in the maternal heart and kidney, together
with decreased plasma creatine concentration, decreasing
urinary creatine excretion, and shifts in tissue-specific
mRNA and protein expression of the enzymes AGAT and
GAMT, and gene expression of CrT1. Whether mainten-
ance of maternal creatine homeostasis is critical for fetal
growth, and whether similar changes occur in human preg-
nancy is unknown and should be the focus of future
studies.
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